Companies Dominating the Mometasone Furoate Landscape
- Perrigo Company plc
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Bausch Health Companies Inc.
- Glenmark Pharmaceuticals Limited
- Vetoquinol USA
- AstraZeneca plc
- Intersect ENT
- Hikma Pharmaceuticals
- Medlab Pharmaceuticals Private Limited
- AdvaCare Pharma
- Dermocare Laboratories
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of mometasone furoate is evaluated at USD 1.14 billion.
The mometasone furoate market size was over USD 1.07 billion in 2024 and is poised to exceed USD 2.64 billion by 2037, growing at over 7.2% CAGR during the forecast period i.e., between 2025-2037. The market growth is owing to rising uncontrolled asthmatic conditions, which affect both children and adults.
North America industry is likely to hold largest revenue share of 47% by 2037, propelled by surge in the number of awareness campaigns regarding psoriasis, coupled with the high prevalence of skin conditions like eczema in the region.
The major players in the market are Bausch Health Companies Inc., Glenmark Pharmaceuticals Limited, Vetoquinol USA, AstraZeneca plc, Intersect ENT, Hikma Pharmaceuticals, Medlab Pharmaceuticals Private Limited, AdvaCare Pharma, Dermocare Laboratories, Taro Pharmaceutical Industries Ltd., Kyorin Remedio Co., Ltd, Teikoku Seiyaku Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals., and others.
